

Wael Saber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5527616/publications.pdf>

Version: 2024-02-01

258
papers

8,600
citations

53794

45
h-index

53230

85
g-index

263
all docs

263
docs citations

263
times ranked

8637
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	3.5	10
2	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	3.5	87
3	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
4	Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 112.e1-112.e9.	1.2	4
5	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	7.1	32
6	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
7	Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012. <i>Bone Marrow Transplantation</i> , 2022, 57, 881-888.	2.4	7
8	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Blastic Plasmacytoid Dendritic Cell Neoplasm: A CIBMTR Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S121-S122.	1.2	0
9	Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia. <i>Leukemia</i> , 2022, 36, 1227-1236.	7.2	8
10	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 911-917.	2.4	18
11	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	1.2	26
12	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined <sc>CIBMTR</sc>/<sc>CMWP</sc> of a <sc>EBMT</sc> analysis. <i>British Journal of Haematology</i> , 2022, 198, 785-789.	2.5	2
13	Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7006-7006.	1.6	6
14	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
15	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	4.1	12
16	Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 270.e1-270.e6.	1.2	17
17	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	1.4	34
18	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 229-233.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983.	5.2	27
20	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
21	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
22	Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29067.	1.5	2
23	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
24	A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7017-7017.	1.6	1
25	The clinical and functional effects of TERT variants in myelodysplastic syndrome. <i>Blood</i> , 2021, 138, 898-911.	1.4	27
26	Optimal treatment regimes for competing risk data using doubly robust outcome weighted learning with bi-level variable selection. <i>Computational Statistics and Data Analysis</i> , 2021, 158, 107167.	1.2	4
27	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339.	1.6	72
28	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1878-1887.	1.6	14
29	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11
30	Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 685.e1-685.e8.	1.2	2
31	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
32	Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 659.e1-659.e6.	1.2	5
33	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
34	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	1.2	0
35	Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥ 1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis. <i>Blood</i> , 2021, 138, 3929-3929.	1.4	2
36	Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis. <i>Blood</i> , 2021, 138, 414-414.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 421-421.	1.4	0
38	Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 320-320.	1.4	0
39	COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study. <i>Blood</i> , 2021, 138, 2611-2611.	1.4	0
40	Trends in Use and Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Racial/Ethnic Minorities. <i>Blood</i> , 2021, 138, 427-427.	1.4	10
41	Superior Outcomes with Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - a Comparative Analysis By CIBMTR. <i>Blood</i> , 2021, 138, 912-912.	1.4	3
42	Germline-Somatic Interactions in Myelofibrosis Susceptibility. <i>Blood</i> , 2021, 138, 313-313.	1.4	0
43	MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. <i>Blood</i> , 2021, 138, 2955-2955.	1.4	0
44	The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2021, 138, 417-417.	1.4	0
45	Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4044-4044.	1.4	0
46	Identification of Novel Prognostic Biomarkers DDX11 and CHD1 of Allogeneic Hematopoietic Cell Transplantation Outcomes for Patients with MDS: A CIBMTR Comprehensive Genomic Screening. <i>Blood</i> , 2021, 138, 3681-3681.	1.4	0
47	Genomic Subgroups Impact Post-Transplant Survival in Patients with Myelodysplastic Syndrome: A CIBMTR Analysis. <i>Blood</i> , 2021, 138, 3678-3678.	1.4	0
48	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
49	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. <i>Bone Marrow Transplantation</i> , 2020, 55, 698-707.	2.4	4
50	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
51	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
52	Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 884-892.	2.0	15
53	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. <i>JAMA Oncology</i> , 2020, 6, 486.	7.1	39
54	Comparison of outcomes of HCT in blast phase of <i>t(9;22)(q34;q11) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14

#	ARTICLE	IF	CITATIONS
55	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
56	Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 805-813.	2.0	7
57	Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL ⁻ negative MPN in blast phase. <i>Blood Advances</i> , 2020, 4, 5562-5573.	5.2	28
58	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
59	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
60	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
61	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2372-2377.	2.0	19
62	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
63	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. <i>Blood</i> , 2020, 136, 3070-3081.	1.4	25
64	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
65	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
66	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
67	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1747-1756.	2.0	7
68	Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S66.	2.0	1
69	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1247-1256.	2.0	139
70	Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020, 189, 1171-1181.	2.5	58
71	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
72	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 893-901.	2.0	13

#	ARTICLE	IF	CITATIONS
73	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49
74	Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S12.	2.0	3
75	MLL-Rearranged AML Is Associated with Poor Outcomes As Compared to Patients with Intermediate- and Adverse-Risk Disease: A CIBMTR Study of 3779 Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S10-S11.	2.0	0
76	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
77	A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. <i>Blood</i> , 2020, 136, 19-21.	1.4	12
78	Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study. <i>Blood</i> , 2020, 136, 15-16.	1.4	2
79	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. <i>Blood</i> , 2020, 136, 32-33.	1.4	2
80	Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis. <i>Blood</i> , 2020, 136, 43-44.	1.4	1
81	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
82	Chromosomal Aberrations in Pre-HCT Blood Samples and Outcomes after Transplantation in Patients with Myelofibrosis. <i>Blood</i> , 2020, 136, 4-5.	1.4	0
83	Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee. <i>Blood</i> , 2020, 136, 27-29.	1.4	0
84	Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults. <i>Blood</i> , 2020, 136, 41-42.	1.4	3
85	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
86	Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz048.	2.9	6
87	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2086-2090.	2.0	42
88	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) with Antecedent History of Philadelphia-Negative Myeloproliferative Neoplasm with De Novo AML and with AML Arising from Myelodysplastic Syndrome: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S107.	2.0	0
89	Community Health Status and Its Association with Patient Outcome Post Allogeneic Hematopoietic Cell Transplantation [HS1]2500 Character Limit of Body of Abstract without Spaces or Title. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S34.	2.0	1
90	HLA-Matched Sibling Versus Haploidentical Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S59-S60.	2.0	0

#	ARTICLE	IF	CITATIONS
91	Acute Gvhd Diagnosis and Adjudication in a Multicenter Trial – a Report from the BMT CTN 1202 Biorepository Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S54.	2.0	0
92	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
93	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
94	HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019, 3, 2581-2585.	5.2	27
95	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23
96	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. <i>Haematologica</i> , 2019, 104, 1084-1092.	3.5	46
97	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e33-e38.	2.0	10
98	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients. <i>Blood</i> , 2019, 134, 253-253.	1.4	1
99	Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT). <i>Blood</i> , 2019, 134, 4585-4585.	1.4	1
100	Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. <i>Blood</i> , 2019, 134, 3323-3323.	1.4	2
101	Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome. <i>Blood</i> , 2019, 134, 4557-4557.	1.4	1
102	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019, 134, 261-261.	1.4	5
103	Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2036-2036.	1.4	1
104	Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index. <i>Blood</i> , 2019, 134, 4603-4603.	1.4	0
105	Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801). <i>Blood</i> , 2019, 134, 2005-2005.	1.4	0
106	Pediatric Intensive Care Resource Utilization Following Hematopoietic Cell Transplantation in Children with Acute Leukemia. <i>Blood</i> , 2019, 134, 3428-3428.	1.4	0
107	Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. <i>Blood</i> , 2019, 134, 4271-4271.	1.4	0
108	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	3.5	38

#	ARTICLE	IF	CITATIONS
109	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	2.4	7
110	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7
111	Peripheral Blood Grafts for T Cellâ€“Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
112	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
113	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
114	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
115	Estimating Propensity Scores for the Receipt of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Outcomes Research Using Claims Data: A Machine Learning Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S304-S305.	2.0	1
116	Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S302.	2.0	5
117	Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S301-S302.	2.0	2
118	Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 797-805.	1.8	6
119	Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1111-1118.	2.0	22
120	Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2072-2080.	2.0	50
121	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. <i>Blood</i> , 2018, 132, 4289-4289.	1.4	1
122	Lost to Follow-up Rates Are Higher in Pediatric Than Adult Survivors, but Not By Transplant Type: A Report from the Center for International Blood and Marrow Transplant Research. <i>Blood</i> , 2018, 132, 2260-2260.	1.4	3
123	The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study. <i>Blood</i> , 2018, 132, 4788-4788.	1.4	1
124	Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Blood</i> , 2018, 132, 832-832.	1.4	1
125	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee. <i>Blood</i> , 2018, 132, 206-206.	1.4	3
126	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. <i>Blood</i> , 2018, 132, 3456-3456.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 704-704.	1.4	0
128	Area-Based Socioeconomic Status and Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Outcomes: A CIBMTR Analysis. <i>Blood</i> , 2018, 132, 714-714.	1.4	0
129	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. <i>Cancer</i> , 2017, 123, 2025-2034.	4.1	48
130	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <i>Cancer</i> , 2017, 123, 2035-2042.	4.1	14
131	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	4.1	73
132	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775.	2.0	41
133	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	27.0	586
134	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	1.4	278
135	Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1021-1028.	2.0	36
136	Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 3346-3355.	4.1	25
137	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
138	Post-Relapse Survival in Lymphoma Patients (Pts) after Experiencing Therapy Failure Following an Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S48.	2.0	0
139	Stratification of Allogeneic Hematopoietic Cell Transplant Patients by Risk of Developing Venous Occlusive Disease: A Model for Assigning a Risk Score. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S302-S303.	2.0	2
140	Importance of Site Preparation in Reducing the Risk of Bacterial Contamination during Bone Marrow Harvest. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S184-S185.	2.0	0
141	Lessons Learned From Merging CIBMTR Data and CMS Medicare Claims Data. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S414-S415.	2.0	3
142	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979.	2.0	16
143	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.	3.5	43
144	Alpha-1 antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017, 92, E610-E611.	4.1	7

#	ARTICLE	IF	CITATIONS
145	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1955-1960.	2.0	24
146	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 42-49.	4.1	46
147	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 367-378.	2.0	50
148	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneic HCT: A CIBMTR Report. <i>Blood</i> , 2017, 130, 667-667.	1.4	2
149	Donor and recipient sex in allogeneic stem cell transplantation: what really matters. <i>Haematologica</i> , 2016, 101, 1260-1266.	3.5	54
150	Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. <i>American Journal of Hematology</i> , 2016, 91, 322-329.	4.1	72
151	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
152	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, 1426-1433.	3.5	53
153	Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 478-484.	2.5	39
154	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 379-386.	0.4	17
155	Prospective, Multicenter Clinical Trial of Atorvastatin-Based Acute Graft-Versus-Host-Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S47-S48.	2.0	1
156	Association of Pre-Transplant Depression with Clinical Outcomes and Resource Utilization after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S22-S23.	2.0	0
157	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1056-1064.	2.0	26
158	Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1306-1312.	2.0	53
159	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
160	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
161	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016, 127, 2427-2438.	1.4	403
162	The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1460-1466.	2.0	6

#	ARTICLE	IF	CITATIONS
163	Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1738-1746.	2.0	23
164	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
165	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 744-751.	2.0	41
166	Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1024-1029.	2.0	39
167	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 932-940.	2.0	43
168	Healthcare Costs and Utilization for Acute Myeloid Leukemia (AML) Patients Aged 50-64 Treated with Chemotherapy (Chemo) ± Allogeneic Hematopoietic Cell Transplantation (alloHCT): Retrospective Cohort Study Using a Large Administrative Claims Database. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S285.	2.0	0
169	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 69-69.	1.4	2
170	Stratification of Allogeneic Hematopoietic Cell Transplant By Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score. <i>Blood</i> , 2016, 128, 983-983.	1.4	3
171	Patient and provider preferences: Treatment summary and survivorship care plans after hematopoietic cell transplant. <i>Journal of Clinical Oncology</i> , 2016, 34, 63-63.	1.6	3
172	Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 2256-2256.	1.4	0
173	Role of Donor Source on Clinical Outcomes and Inpatient Resource Utilization for Hematopoietic Cell Transplantation in Children with Acute Leukemia. <i>Blood</i> , 2016, 128, 3575-3575.	1.4	0
174	Impact of Obesity on Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. <i>Blood</i> , 2016, 128, 4667-4667.	1.4	0
175	Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Plasma Levels of CXCL-Chemokines (CXCL-4 and CXCL-7) in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 4678-4678.	1.4	0
176	Patient and Provider Preferences for Survivorship Care Plans for Allogeneic Hematopoietic Cell Transplantation (HCT) Survivors: A Qualitative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S174-S175.	2.0	0
177	Administrative Claims Data for Cost Analyses in Hematopoietic Cell Transplantation: The Good, the Bad and the Ugly. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S359-S360.	2.0	0
178	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
179	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33
180	Impact of Race on Graft-Versus-Host Disease Rates after HLA-Matched Sibling Bone Marrow or Peripheral Blood Hematopoietic Cell Transplantation: Comparison of North American Caucasian Versus Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S34-S35.	2.0	1

#	ARTICLE	IF	CITATIONS
181	Allogeneic Transplant for Acute Biphentotypic Leukemia: Characteristics and Outcome in the CIBMTR Database. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S83.	2.0	2
182	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S30-S31.	2.0	8
183	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
184	Guidelines for Defining and Implementing Standard Episode of Care for Hematopoietic Stem Cell Transplantation within the Context of Clinical Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 583-588.	2.0	18
185	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1046-1053.	2.0	133
186	HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1783-1789.	2.0	83
187	Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1863-1869.	2.0	342
188	Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1883-1887.	2.0	36
189	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
190	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49
191	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTR®) Study. <i>Blood</i> , 2015, 126, 2003-2003.	1.4	1
192	Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2017-2017.	1.4	2
193	The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 265-265.	1.4	3
194	A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 528-528.	1.4	4
195	A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 64-64.	1.4	0
196	Outcomes of Allogeneic Transplantation in Patients Aged ≥ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR® Cohort Analysis. <i>Blood</i> , 2015, 126, 2009-2009.	1.4	0
197	Myelodysplastic syndromes in the United States: an update for clinicians. <i>Annals of Medicine</i> , 2014, 46, 283-289.	3.8	22
198	Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 57-65.	2.3	11

#	ARTICLE	IF	CITATIONS
199	Plerixafor and Abbreviated-Course Granulocyte Colony-Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1926-1931.	2.0	23
200	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1566-1572.	2.0	24
201	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
202	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
203	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146
204	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 89-97.	2.0	130
205	Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen-Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 421-424.	2.0	13
206	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
207	Long-Term Survival and Late Effects Among 1-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation (2nd Allo HCT) for Relapsed Acute Leukemia and Myelodysplastic Syndrome: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S64.	2.0	0
208	Allotransplantation for Patients Age \geq 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
209	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
210	Incidence and Risk Factors for the Development of Idiopathic Pneumonitis Syndrome (IPS) after Autologous Hematopoietic Cell Transplantation (AutoHCT) for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S106.	2.0	0
211	HLA-Mismatch Is Associated with Worse Outcomes after Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S25-S26.	2.0	1
212	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation (AutoHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S45-S46.	2.0	2
213	Safety of Outpatient Autologous Hematopoietic Cell Transplantation (AuHCT) for Multiple Myeloma and Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S114.	2.0	3
214	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98
215	Outcomes of Human Leukocyte Antigen-Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1390-1398.	2.0	18
216	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	1.4	228

#	ARTICLE	IF	CITATIONS
217	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. <i>Blood</i> , 2014, 123, 3664-3671.	1.4	730
218	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. <i>Blood</i> , 2014, 124, 2534-2534.	1.4	1
219	Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. <i>Blood</i> , 2014, 124, 319-319.	1.4	6
220	FLT3 Mutation Increases Relapse Risk after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia in First or Second Complete Remission: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2014, 124, 322-322.	1.4	4
221	Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2014, 124, 422-422.	1.4	6
222	Early rituximab failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility of autologous hematopoietic cell transplantation (AHCT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7048-7048.	1.6	0
223	Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) for hematopoietic progenitor cell (HPC) mobilization in AL amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8606-8606.	1.6	0
224	Impact of palifermin use on pediatric patient (PedPts) hematopoietic cell transplant (HCT) outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7117-7117.	1.6	0
225	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
226	Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 746-753.	2.0	83
227	The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. <i>Blood</i> , 2013, 121, 4800-4806.	1.4	44
228	Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1368-1373.	2.0	29
229	Clinical Outcomes of Hematopoietic Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma Transformed From Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S157-S158.	2.0	0
230	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1615-1624.	2.0	99
231	Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 625-631.	2.0	91
232	Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 1669-1676.	1.6	69
233	Autologous haematopoietic cell transplantation for non Hodgkin lymphoma with secondary CNS involvement. <i>British Journal of Haematology</i> , 2013, 162, 648-656.	2.5	29
234	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013, 122, 1974-1982.	1.4	92

#	ARTICLE	IF	CITATIONS
235	Validation and Refinement Of The Disease Risk Index For Stratification Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Study Of 13,131 Patients From The Center For International Blood & Marrow Transplant Research. <i>Blood</i> , 2013, 122, 548-548.	1.4	0
236	Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intensity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis. <i>Blood</i> , 2013, 122, 2093-2093.	1.4	10
237	Alternative Donor Transplantation For Adults With Lymphoma: Comparison Of Umbilical Cord Blood Versus 8/8 HLA-Matched Donor (URD) Versus 7/8 URD. <i>Blood</i> , 2013, 122, 161-161.	1.4	6
238	Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. <i>Blood</i> , 2012, 119, 3908-3916.	1.4	228
239	HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1302-1308.	2.0	15
240	Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1446-1454.	2.0	22
241	Comparison of Outcomes After Related and Unrelated Hematopoietic Cell Transplantation in Adults with Myelodysplastic Syndromes: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , 2012, 120, 355-355.	1.4	1
242	Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes. <i>Blood</i> , 2012, 120, 467-467.	1.4	0
243	Lille Scoring System Rather Than DIPSS Is a Better Predictive of Overall Mortality After Allogeneic Hematopoietic Cell Transplantation (HCT) for Primary Myelofibrosis Using Reduced Intensity Conditioning: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , 2012, 120, 432-432.	1.4	0
244	Lower Transplant-Related Mortality and Improved Survival for Patients with AML in First CR Receiving BuCy Compared to Cy/TBI As Myeloablative Preparation for Allogeneic Transplantation: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , 2012, 120, 217-217.	1.4	0
245	Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A Cibmtr Analysis. <i>Blood</i> , 2012, 120, 473-473.	1.4	8
246	Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis. <i>Blood</i> , 2012, 120, 815-815.	1.4	1
247	Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1862-1868.	2.0	109
248	Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum?. <i>Blood</i> , 2011, 118, 3092-3092.	1.4	1
249	Results of Allogeneic Hematopoietic Cell Transplantation in Persons with Fanconi Anemia and Pretransplant Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. <i>Blood</i> , 2011, 118, 838-838.	1.4	0
250	HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. <i>Blood</i> , 2011, 118, 3094-3094.	1.4	0
251	Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2010, 116, 3506-3506.	1.4	1
252	RESULTS of Allogeneic TRANSPLANTATION for Polycythemia VERA and Essential Thrombocythemia. <i>Blood</i> , 2010, 116, 3514-3514.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. <i>Leukemia Research</i> , 2008, 32, 913-918.	0.8	37
254	Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1560-1566.	1.3	6
255	Independent Risk Factors of Catheter-Related Thrombosis (CRT) in Adult Cancer Patients: An Individual Patient-Level Data (IPD) Meta-Analysis of Randomized Clinical Trials and Prospective Cohort Studies. <i>Blood</i> , 2008, 112, 3814-3814.	1.4	0
256	Time to Post-Remission Therapy (PRT) Is an Independent Prognostic Factor for Relapse and Overall Survival in Adults with Acute Lymphocytic Leukemia (ALL).. <i>Blood</i> , 2006, 108, 1883-1883.	1.4	1
257	c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML.. <i>Blood</i> , 2006, 108, 4510-4510.	1.4	1
258	CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2005, 106, 3292-3292.	1.4	0